RM2 antigen (beta1,4-GalNAc-disialyl-Lc4) as a new marker for prostate cancer.
RM2 antigen (beta1,4-GalNAc-disialyl-Lc4) as a new marker for prostate cancer.
复制标题
RM2 抗原（β1,4-GalNAc-disialyl-Lc4）作为前列腺癌的新标志物。
DOI：
10.1002/ijc.20868
复制
发表时间：
2005
影响因子：
6.4
通讯作者：
Arai,Yoichi
中科院分区：
文献类型：
--
作者：
Saito,Seiichi;Egawa,Shin;Endoh,Mareyuki;Ueno,Seiji;Ito,Akihiro;Numahata,Kenji;Satoh,Makoto;Kuwao,Sadahito;Baba,Shiro;Hakomori,Senitiroh;Arai,Yoichi
虽然前列腺特异性抗原（PSA）已被广泛用于前列腺癌的早期检测，但PSA在特异性和预测病理分期方面存在问题。因此，迫切需要一种新的前列腺癌标志物。我们使用75例根治性前列腺切除术标本检测了一种新的碳水化合物抗原β 1，4-GalNAc-disialyl-Lc 4（由单克隆抗体RM 2定义）在前列腺癌中的表达。RM 2免疫反应性在所有良性腺体中为阴性至弱，在高级别前列腺上皮内瘤变中为弱至中度。在前列腺癌中，20例RM 2免疫反应性为阴性至弱（低表达），55例为中至强（高表达）。格里森模式3和≥4之间观察到RM 2表达水平存在明显差异。RM 2抗原的高表达与原发Gleason分型≥4、Gleason评分≥8、肿瘤体积较大、肿瘤分期较晚有关。此外，高表达组的5年无PSA失败生存率显著较低。RM 2表达水平与术前血清PSA无明显相关性。前列腺癌细胞系PC 3和LNCap中的蛋白质印迹分析显示，两种细胞的主要49 kDa和次要39 kDa糖蛋白是共同的，但LNCap特有的59和125 kDa糖蛋白增加，PC 3特有的88和98 kDa糖蛋白增加。RM 2抗原是一种新的前列腺癌组织学标志物，可反映Gleason分级系统。携带RM 2抗原的糖蛋白的鉴定将为前列腺癌的性质提供新的见解。© 2005 Wiley利斯公司
Although prostate‐specific antigen (PSA) has been widely used for early detection of prostate cancer, PSA has problems with specificity and prediction of pathological stage. Therefore, a new marker for prostate cancer is urgently required. We examined expression of a novel carbohydrate antigen, β1,4‐GalNAc‐disialyl‐Lc4, defined by the monoclonal antibody RM2, in prostate cancer using 75 cases of radical prostatectomy specimens. RM2 immunoreactivity was negative to weak in all benign glands, and weak to moderate in high‐grade prostatic intraepithelial neoplasia. In prostatic adenocarcinoma, RM2 immunoreactivity was negative to weak (lower expression) in 20 cases, and moderate to strong (higher expression) in 55 cases. A clear difference of RM2 expression level was observed between Gleason patterns 3 and ≥4. Higher expression of RM2 antigen was significantly associated with primary Gleason pattern ≥4, high Gleason score (≥8), larger tumor volume and advanced tumor stage. Furthermore, 5‐year PSA failure‐free survival was significantly lower in the higher expression group. However, no significant relationship was observed between RM2 expression level and preoperative serum PSA. Western blot analysis in prostate cancer cell lines PC3 and LNCap revealed that major 49‐kDa and minor 39‐kDa glycoproteins were common to both cells, but there was an increase of 59‐ and 125‐kDa glycoproteins unique to LNCap and an increase of 88‐ and 98‐kDa glycoproteins unique to PC3. RM2 antigen is a new histological marker for prostate cancer that may reflect the Gleason grading system. Identification of the glycoproteins carrying the RM2 antigen will provide new insights into the properties of prostate cancer. © 2005 Wiley‐Liss, Inc.